news:: Drug Discovery in Academia
Back to Drug Discovery in Academia

Participating Entities

AstraZeneca Pharmaceuticals
AstraZeneca is a global, innovation-driven, integrated biopharmaceutical company.
Our mission is to make a meaningful difference to patient health through great medicines that bring benefit for patients and add value for our stakeholders and society.
We discover, develop, manufacture and market prescription medicines for six important areas of healthcare, which include some of the world’s most serious illnesses: cancer, cardiovascular, gastrointestinal, infection, neuroscience, and respiratory and inflammation.

BioPontis Alliance
BioPontis Alliance is led by industry veterans who are committed to advancing novel biological research by bringing their collective experience in technical, regulatory, commercial, and scientific development into early stage biomedical product creation; a commitment fueled by the clear understanding that medicine will not advance without a solution to the feasibility gap.

CHDI Foundation, Inc.
CHDI Foundation, Inc. is a privately-funded, not-for-profit, virtual biotech company that is exclusively dedicated to rapidly discovering and developing therapies that slow the progression of Huntington's disease (HD). Our scientists work closely with a network of more than 600 researchers in academic and industrial laboratories around the world in the pursuit of these novel therapies, providing project management to ensure that our common goals remain in focus. This helps bridge the translational gap that often exists between academic and industrial research pursuits that adds costly delays to therapy development. In its role as a collaborative enabler, CHDI seeks to bring the right partners together to identify and address critical scientific issues and move drug candidates to clinical evaluation as rapidly as possible. Our activities extend from exploratory biology to the identification and validation of therapeutic targets, and from drug discovery and development to clinical studies and trials. More information about CHDI can be found at

Corporate Office of Science and Technology (COSAT), Johnson & Johnson
The Corporate Office of Science and Technology (COSAT) was created in 1978 to foster our company's long-standing focus on innovation and entrepreneurship. It was formed by assembling a team of senior scientists and clinicians whose primary objective is to identify, nurture, and guide emerging technologies and products, ensuring that Johnson & Johnson's long history of success continues well into the future.
COSAT's role within and beyond the Johnson & Johnson operating company structure is to: Identify and nurture emerging technologies related to health care; Assess technical risk and business potential of these technologies; Facilitate the incorporation of these technologies into the Johnson & Johnson Family of Companies.

The Eisai Neuroscience Product Creation Unit
Eisai, Inc.

The Eisai Neuroscience Product Creation Unit was established in 2009 when Eisai designated integrative neuroscience as a therapeutic area of focus.  The unit has major research facilities in Hatfield, UK, Woodcliff Lake, NJ, and Tsukuba, Japan that are engaged in developing innovative new drugs to satisfy unmet medical needs worldwide.   Eisai has been committed to the therapeutic area of neurology for more than a decade, developing products that have been approved for Alzheimer’s disease and epilepsy.  Eisai Inc. was established in 1995 and is ranked among the top-20 U.S. pharmaceutical companies (based on retail sales). For more information about Eisai, please visit 

GlaxoSmithKline Research & Development
Our scientists are working hard to discover new ways of treating and preventing diseases. By combining the wide-ranging talents of our R&D employees with our leading edge science resources, we are dedicated to bringing more medicines of value to patients.
Our product pipeline is diverse and changes over time as new molecules progress from discovery to development and ultimately to approval where they become available to patients.
But this process requires time and investment. It takes about 12-15 years and costs over £500 million to discover and develop a new medicine or vaccine, so we need to be determined and innovative to help new molecules progress into medicines. One of our aims is to try to shorten the amount of time it takes to safely develop these medicines and vaccines.
We are one of the largest collaborators in industry and work with academic institutions, governments, and other pharmaceutical and biotechnology companies. We believe that the strength of our combined efforts will ultimately help people do more, feel better and live longer.

Maryland Biotechnology Center
The Maryland Biotechnology Centeris a newly created organization within the Maryland Department of Business and Economic Development (DBED) that consolidates and coordinates a host of state, university and private sector initiatives to better showcase and support biotechnology innovation and entrepreneurship in Maryland. Working closely with industry partners, the Center will concentrate on efforts that create new bioscience enterprises, sustain the growth of successful enterprises, and leverage Maryland’s unique life sciences assets in the academic and federal sectors, to advance Maryland’s role as a global biotechnology leader.

Merck Research Laboratories
Merck discovers, develops, manufactures, and markets vaccines, medicines, and consumer and animal health products designed to help save and improve lives.  Our strategy for growth is based on breakthrough research and development — both internal and external through partnerships.  We welcome partnerships in a number of therapeutic areas – at all stages of development or commercialization -- that address unmet needs for patients, as well as technologies that will enhance the productivity of our research laboratories.  Let's explore how we can combine our strengths with yours, and share our successes together. Visit us at to learn more. 

The National Institute of Neurological Disorders and Stroke (NINDS)
The National Institute of Neurological Disorders and Stroke (NINDS) conducts and supports research on brain and nervous system disorders. Created by the U.S. Congress in 1950, NINDS is one of the more than two dozen research institutes and centers that comprise the National Institutes of Health (NIH). The NIH, located in Bethesda, Maryland, is an agency of the Public Health Service within the U.S. Department of Health and Human Services. NINDS has occupied a central position in the world of neuroscience for more than 50 years.
The mission of the NINDS is to reduce the burden of neurological disease—a burden borne by every age group, every segment of society, and people all over the world. To accomplish this goal the NINDS supports and conducts basic, translational, and clinical research on the normal and diseased nervous system. The Institute also fosters the training of investigators in the basic and clinical neurosciences, and seeks better understanding, diagnosis, treatment, and prevention of neurological disorders.

New Enterprise Associates (NEA)
NEA’s team of world-class investment professionals is deeply committed to helping our partner entrepreneurs and management teams build transformational companies. Our legacy of entrepreneurship—nearly one-third of our investing team members are former entrepreneurs of NEA—and unrivaled domain expertise in our sectors of focus make us an ideal partner for growing businesses.
When you choose to work with NEA, our team becomes your team—ready and able to take the call, answer the question, study the challenge and make a difference.

Pfizer's Centers for
Therapeutic Innovation
Translating Leading Science into Clinical Candidates Through Networked Collaboration
The Centers for Therapeutic Innovation (CTI), a newly created, entrepreneurial Research Unit at Pfizer, Inc. is dedicated to the establishment of global partnerships between Academic Medical Centers (AMCs) and Pfizer to transform research and development through a focus on translational medicine.
The CTI collaborative model will effectively and efficiently combine the best ideas, research and expertise of the AMC with Pfizer's resources. The result of this integration will be better testing of clinical hypotheses, increasing the speed with which we establish Proof-of-Mechanism (PoM) and ultimately bring truly differentiated medicines to patients in need.

Prostate Cancer Foundation
Firmly committed to curing prostate cancer, the Prostate Cancer Foundation is the leading philanthropic organization funding and accelerating research globally.

Since 1993, our unique strategies for identifying and investing in the most promising research programs have generated life-saving results. We channel resources to the world’s top scientific minds—cutting red tape and encouraging collaboration to speed breakthroughs.
As a champion for increased government and private support, PCF has helped build a global research enterprise of nearly $10 billion. Through the generous contributions of our donors, we have funded more than 1,500 programs at nearly 200 research centers in 12 countries.

The Reliable Source for the Latest Developments:  For more than 16 million men and their families fighting prostate cancer globally, PCF is a primary source for new standard-of-care and research information. We connect patients, loved ones, care providers and scientists to critical updates, the latest developments, best practices and news from the treatment pipeline.

Advancing Hope, with Your Help:  Many important discoveries in the fight against prostate cancer since 1993 resulted from PCF funding or coordination—including the development of new medications, gene therapy approaches and the development of vaccines that may soon work with the body’s immune system to kill prostate cancer cells.

Share This Information